Data on the utilization of tamoxifen remain scarce (54–56) and mostly related to the NSABP-P1 trial in which 288 women develop breast cancer; 8 had BRCA1 and 11 had BRCA2 (54). This evidence concerns the gene BRCA2 and breast carcinoma.